NCT07706777 HRS-2129 Primary gout Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07706777—Clinical Study of HRS-2129 for Acute Gouty Arthritis—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07706777 is a hot trial to watch

Primary gout is increasingly segmented by mechanism, biomarker, line of therapy, geography and endpoint architecture. NCT07706777 is notable because it tests HRS-2129 in a Phase 2 design while Change from baseline inVisual Analogous Scale pain score at 24 hours post first dose serves as the main decision variable. The value of this program will depend on whether the protocol converts biological rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add mechanism, development-status and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment. Enrollment of 90 participants across China shapes statistical precision, execution risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

• Primary: Change from baseline inVisual Analogous Scale pain score at 24 hours post first dose — from ICF signing date to 24 hours after first dose
• Secondary: Change from baseline in VAS pain score at 1 hour, 2 hours, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours post first dose — from ICF signing date to 1 hour, 2 hours, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours after first dose
• Secondary: Time until complete disappearance of pain in the target joint — from ICF signing date to 15 days after first dose
• Secondary: Mean daily VAS pain score change from baseline (on-treatment) — from ICF signing date to 15 days after first dose
• Secondary: Safety：Incidence and severity of AE/SAE — from ICF signing date to day 14 after last dose(14 days)

Benchmark readouts in the surrounding field

• EFFICACY AND SAFETY OF HR091506 EXTENDED-RELEASE TABLETS IN PATIENTS WITH GOUT, HYPERURICEMIA, AND RECURRENT FLARES, TOPHI, OR CHRONIC GOUTY ARTHROPATHY: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PHASE 3 TRIAL (Phase 3): SUA(<300 μmol/L) = 40.7 % ( 34.2 - 47.2); SUA(<300 μmol/L) = 63.8 % ( 57.5 - 70.1)
• Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial (Phase 3): TEAE = 89.1 % ; TEAE = 89.7 %
• A Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group, Placebo and Active Comparator-controlled, Dose Finding, and Phase II Study to Assess Efficacy and Safety of LC350189 in Gout Patients With Hyperuricemia (Phase 2): Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 = 2.9 Percentage of participants ; Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 = 47.1 Percentage of participants

These indexed results are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, treatment line, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: HRS-2129 (Phase 2/3; target not reported)

Company & Deal Intelligence context: Shandong Suncadia Medicine Co., Ltd.

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes that connect activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

NCT07706777 is a focused lens on Primary gout development. Its value will be determined by whether HRS-2129 can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from existing benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.